---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-034747"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:03:30.590111+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q4/FY2021 results; Phase 2b enrollment ongoing for ibezapolstat

## Summary
- R&D expense FY2021: $2.0M (vs $2.2M in 2020); Q4 2021: $0.7M (vs $0.5M).
- G&A expense FY2021: $10.8M (vs $2.4M) due to stock-based compensation and professional fees.
- Phase 2a trial for C. difficile infection achieved 100% clinical cure and sustained cure with ibezapolstat.
- Phase 2b enrollment expected to complete in H2 2022, comparing ibezapolstat to vancomycin.
- New microbiome study with University of Houston comparing ibezapolstat to other CDI antibiotics anticipated H2 2022.

## SEC filing metadata
- accession: 0001104659-22-034747
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465922034747/0001104659-22-034747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465922034747/tm229353d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-034747
- JSON: https://secwatch.observer/filing/0001104659-22-034747.json
- Plain text: https://secwatch.observer/filing/0001104659-22-034747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.